IL15RA and neoplasm: Additionally, our team has developed a tumor-conditional anti-PD-L1/IL-15 immunocytokine (LH05), which innovatively employs steric hindrance of its flanking moieties of anti-PD-L1 and IL-15Rα-sushi domain to mask IL-15.110